Loading...
XTSEMBX
Market cap38mUSD
Jan 09, Last price  
0.42CAD
1D
-3.49%
1Q
23.88%
Jan 2017
59.62%
Name

Microbix Biosystems Inc

Chart & Performance

D1W1MN
XTSE:MBX chart
P/E
—
P/S
3.38
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.47%
Rev. gr., 5y
5.71%
Revenues
17m
-13.43%
4,067,4384,376,5793,644,1424,048,8264,993,5216,082,4696,463,2356,228,2926,669,7897,574,5938,396,7968,873,9129,517,13710,185,79812,510,55813,412,34110,524,90418,592,96019,076,24116,514,776
Net income
-39k
L
14,266125,526-2,092,022-2,711,810-3,667,909-2,484,536-2,538,449-2,613,740-2,636,8001,378168,979613,984748,407-3,780,088-8,621,56631,918-6,227,5251,630,1851,788,689-39,483
CFO
-1m
L
444,575372,306-1,576,107-1,807,054-1,953,075-2,185,115-1,813,534-1,299,144-1,750,654428,355-1,170,842595,402913,308297,047-537,00544,3688,5662,106,7363,465,199-1,094,561
Dividend
Sep 02, 19990.275 CAD/sh
Earnings
Feb 12, 2025

Profile

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
URL
https://microbix.com/
IPO date
Oct 01, 1992
Employees
100
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
16,515
-13.43%
19,076
2.60%
Cost of revenue
19,090
16,306
Unusual Expense (Income)
NOPBT
(2,575)
2,771
NOPBT Margin
14.52%
Operating Taxes
77
Tax Rate
2.79%
NOPAT
(2,575)
2,693
Net income
(39)
-102.21%
1,789
9.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,115)
3,444
BB yield
2.61%
-4.77%
Debt
Debt current
265
267
Long-term debt
7,234
6,558
Deferred revenue
Other long-term liabilities
299
Net debt
(4,107)
(6,662)
Cash flow
Cash from operating activities
(1,095)
3,465
CAPEX
(1,016)
(2,026)
Cash from investing activities
(1,016)
(2,026)
Cash from financing activities
229
2,062
FCF
(2,670)
1,903
Balance
Cash
11,606
13,488
Long term investments
Excess cash
10,781
12,534
Stockholders' equity
14,406
15,320
Invested Capital
20,788
18,228
ROIC
14.69%
ROCE
9.01%
EV
Common stock shares outstanding
137,912
141,688
Price
0.31
-39.22%
0.51
-19.05%
Market cap
42,753
-40.84%
72,261
-19.04%
EV
38,646
65,599
EBITDA
(1,418)
3,807
EV/EBITDA
17.23
Interest
839
827
Interest/NOPBT
29.83%